Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + bevacizumab + platinum chemotherapy in EGFR-mutant TKI-failed T790M-negative PD-L1-positive non-squamous NSCLC
ChiCTR2400079991Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Primary endpoint: 6-month progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400079991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079991.